^
    CANCER:

    Bladder Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    cisplatin
    		0
    DNA synthesis inhibitor
    cisplatin + gemcitabine
    gemcitabine
    gemcitabine-releasing intravesical system
    pembrolizumab
    		1
    PD1 inhibitor
    nivolumab
    PD1 inhibitor
    tislelizumab
    avelumab
    		2
    PD-L1 inhibitor
    atezolizumab
    PD-L1 inhibitor
    durvalumab
    5-fluorouracil
    		3
    Thymidylate synthase inhibitor
    5-fluorouracil
    capecitabine
    4
    Tubulin polymerization promoter, DNA synthesis inhibitor
    carboplatin + gemcitabine
    5
    IFNα stimulant
    nadofaragene firadenovec-vncg
    6
    mTOR inhibitor
    everolimus
    7
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    8
    Apoptosis stimulant
    Alpha1H
    9
    Reactive oxygen species stimulant
    AU-011
    10
    IL-15 superagonist
    inbakicept
    11
    FGFR inhibitor
    infigratinib
    futibatinib
    12
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    13
    Multi-tyrosine kinase inhibitor
    anlotinib
    ponatinib
    14
    DNA PK inhibitor
    NU7441
    M3814
    15
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    16
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    17
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    18
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    gemcitabine + paclitaxel
    cisplatin + paclitaxel
    19
    Bifunctional alkylating agent, Topoisomerase II inhibitor, DNA synthesis inhibitor
    gemcitabine + ifosfamide + pegylated liposomal doxorubicin
    cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV
    20
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    21
    Nectin-4-targeted antibody-drug conjugate, Microtubule inhibitor
    enfortumab vedotin-ejfv
    22
    Topoisomerase II inhibitor, Tubulin polymerization promoter
    carboplatin + etoposide IV
    23
    Nectin-4-targeted antibody-drug conjugate, PD1 inhibitor, Microtubule inhibitor
    pembrolizumab + enfortumab vedotin-ejfv
    24
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + 5-fluorouracil
    25
    Cell death stimulant, GM-CSF agonist
    CG0070
    26
    Immunotherapy
    Immunotherapy
    27
    CTLA4 inhibitor
    CTLA4 inhibitor
    ddMVAC
    		28
    Chemotherapy
    GC
    EP
    29
    PARP inhibitor
    PARP inhibitor
    30
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    31
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    disitamab vedotin
    ado-trastuzumab emtansine
    32
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    tislelizumab + disitamab vedotin
    33
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    34
    PD1 inhibitor, GDF15 inhibitor
    nivolumab + CTL-002
    35
    DNA synthesis inhibitor, Cytidine deaminase inhibitor, DNA methylation inhibitor
    gemcitabine + EPI01
    36
    WDR5 inhibitor
    OICR-9429
    37
    BRD3 inhibitor, BRD4 inhibitor, BRD2 inhibitor
    OTX015
    38
    ATR inhibitor
    M6620
    39
    KRAS G12C inhibitor
    sotorasib
    40
    PD-L1 inhibitor, NK cell stimulant
    avelumab + CYNK-101
    41
    FGFR3-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AMB302
    42
    KRAS G12C inhibitor, mTORC1 inhibitor
    adagrasib + nanoparticle albumin-bound rapamycin
    sotorasib + nanoparticle albumin-bound rapamycin
    43
    GPC-1-targeted antibody-drug conjugate
    anti-GPC-1 ADC
    44
    CA6-targeted antibody-drug conjugate, Microtubule inhibitor
    SAR566658
    45
    FGFR3-targeted antibody-drug conjugate, Microtubule inhibitor
    LY3076226
    46
    Integrin beta-6 -targeted antibody-drug conjugate, Microtubule inhibitor
    SGN-B6A
    47
    EGFR inhibitor
    cetuximab
    48
    DDX5 degrader
    FL118
    49
    EZH2 inhibitor
    GSK2816126
    50
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    51
    Tyrosine kinase inhibitor
    PD173074
    52
    PIK3C3 inhibitor, FGFR inhibitor
    MPT0L145
    53
    C4.4a-targeted antibody-drug conjugate, Microtubule inhibitor
    BAY1129980
    54
    MAT2A inhibitor
    IDE397
    55
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    No biomarker
    PD-L1 expression
    HER-2 positive
    HER-2 expression
    PD-L1 overexpression
    HER-2 amplification
    HER-2 overexpression
    DDR + PD-L1 expression
    PD-L1 elevation
    FGFR3 mutation
    ERCC2 E606Q
    TSC1 1907_1908del
    TSC1 mutation
    ERCC2 mutation
    FGFR3 S249C
    FGFR3 R248C
    FGFR3 G370C
    FGFR3 overexpression
    FGFR3 K508M
    FGFR3 S247C
    CCDC69 overexpression
    PIK3CA M1043I
    MSH4 L359I
    FGFR3-TACC3 fusion
    TMB-H
    FGFR2 mutation
    FGFR1 amplification
    TET1 mutation
    BIRC5 expression
    RB1 mutation + PD-L1 expression
    RB1 mutation
    PBRM1 mutation
    BRCA2 mutation
    PD-1 expression
    ARID1A mutation
    PTEN expression
    IFNA1 expression
    IFNG expression
    PCSK9 underexpression
    CXCL13 expression
    RNF43 mutation
    KMT2C mutation
    TLR4-L
    KIFC1 expression
    CREBBP mutation
    BRCA1 underexpression
    ERCC1 underexpression
    CALCR overexpression
    GNG4 overexpression
    CD8 overexpression
    ITGAX underexpression
    VTCN1 overexpression
    SAAL1 overexpression
    CD163 overexpression
    CD68 overexpression
    B2M overexpression
    PD-L1 overexpression + APOBEC3B overexpression
    TMB-H + RB1 mutation + PD-L1 underexpression
    PD-L1 expression + TMB-H
    LAMP3 expression
    CXCL10 expression
    CXCL10 overexpression + LAMP3 overexpression
    SLC35A2 overexpression
    SRRM4 overexpression
    TMEM72 underexpression
    NPHS1 underexpression
    ITIH5 overexpression
    FGFR1 overexpression
    PIK3CA mutation + MSI-L/dMMR
    High MHC-II signature
    12-CK gene signature
    DDR
    SBS5 signature
    IFNG gene signature
    COL6A1 overexpression
    HRAS Q61
    ERBB3 expression
    MAST4 mutation
    HRAS mutation
    KRAS mutation
    HLA-A*03
    TDO2 overexpression
    RAD52 underexpression
    LYPD3 expression
    MTAP deletion
    HYAL4 V1
    WDR5 overexpression
    ERBB3 mutation + TMB-H
    HER-2 mutation + TMB-H
    OXCT1 expression
    TP53 mutation
    NOTCH1 mutation + MSI-L/dMMR
    FGFR3-BAIAP2L1 fusion
    PTEN deletion + KRAS G12C
    ELF3 mutation + MSI-L/dMMR
    ELF3 mutation + TMB-L + MSI-L/dMMR
    NOTCH1 mutation + TMB-L + MSI-L/dMMR
    KRAS G12C
    GSDMB expression
    GPC1 overexpression
    CA6 expression
    ITGB6 expression
    ATM deletion
    TUBA1C overexpression
    YTHDC1 underexpression
    H19 overexpression
    KRT20 overexpression